Atlas Systems bags new deal from US based healthcare IT solutions provider

 

Princeton, NJ, January 19, 2015 -- Atlas Systems Inc. is pleased to announce that it has signed a deal with US based Technology Solutions company for their Electronic Health Record (EHR) solution upgrade.

Atlas System was chosen to upgrade the current client-server application to conform to current government regulations, within the deadline set by the regulatory authorities. The client has health integration framework that connects physicians and other healthcare professionals giving them secure access to data in a patient’s EHR and enabling health teams to have access to the accurate and up-to date information they need.

As part of the deal, Atlas’ highly qualified set of experts will perform the upgrade during the specified hours and meet the deadline related to the regulatory compliance and strengthen the availability, reliability of the application and keep it current. This strategic contract is an offshore engagement aiming to provide an optimal combination agility, flexibility and quality required by the client.

Atlas has established a strong footprint in the US and global space with the latest and most technically advanced tools to build a state-of-the art solution that fits the emerging Information technology needs of each industry. With this win, Atlas Systems continues to ensure we are able to offer our customers the efficiencies they need whilst allowing us to focus on the right blend of service innovation and creativity.

About Atlas: Atlas Systems Inc. is a leading technology innovator, offering software and service solutions to global and mid-market companies in a range of different industries, including BFSI, Healthcare& Finance, Insurance and Manufacturing. Atlas Systems proprietary products such as ComplyScore® and PRIME® provide a range of GRC and provider solutions. Our Learning, Technology and Oracle solutions provide future ready, tailor made services to enterprises across the globe. The goal is to deliver serious and competitively priced products and services to our clients that add business value that will have positive impact on their business.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup